James H Doroshow

James H Doroshow

UNVERIFIED PROFILE

Are you James H Doroshow?   Register this Author

Register author
James H Doroshow

James H Doroshow

Publications by authors named "James H Doroshow"

Are you James H Doroshow?   Register this Author

100Publications

3124Reads

22Profile Views

From the Broad Phase II Trial to Precision Oncology: A Perspective on the Origins of Basket and Umbrella Clinical Trial Designs in Cancer Drug Development.

Cancer J 2019 Jul/Aug;25(4):245-253

Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000386DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6658138PMC
July 2020

Dexamethasone and Tofacitinib suppress NADPH oxidase expression and alleviate very-early-onset ileocolitis in mice deficient in GSH peroxidase 1 and 2.

Life Sci 2019 Nov 2:116884. Epub 2019 Nov 2.

Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, NIH, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lfs.2019.116884DOI Listing
November 2019

Identification of pharmacodynamic biomarkers and common molecular mechanisms of response to genotoxic agents in cancer cell lines.

Cancer Chemother Pharmacol 2019 Oct 31;84(4):771-780. Epub 2019 Jul 31.

Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, 9609 Medical Center Dr., Rockville, MD, 20850, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-019-03898-zDOI Listing
October 2019

Hydrogen peroxide-producing NADPH oxidases and the promotion of migratory phenotypes in cancer.

Arch Biochem Biophys 2019 Oct 12;675:108076. Epub 2019 Aug 12.

Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, 20892, USA; Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, MD, 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.abb.2019.108076DOI Listing
October 2019

Exposure time versus cytotoxicity for anticancer agents.

Cancer Chemother Pharmacol 2019 Aug 17;84(2):359-371. Epub 2019 May 17.

Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, 20852, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-019-03863-wDOI Listing
August 2019

Modulation of selenium-dependent glutathione peroxidase activity enhances doxorubicin-induced apoptosis, tumour cell killing and hydroxyl radical production in human NCI/ADR-RES cancer cells despite high-level P-glycoprotein expression.

Free Radic Res 2019 Aug 30;53(8):882-891. Epub 2019 Jul 30.

Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda , MD , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10715762.2019.1641602DOI Listing
August 2019

RNA Sequencing of the NCI-60: Integration into CellMiner and CellMiner CDB.

Cancer Res 2019 Jul 21;79(13):3514-3524. Epub 2019 May 21.

Developmental Therapeutic Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-18-2047DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615556PMC
July 2019

Evaluation of Pharmacodynamic Responses to Cancer Therapeutic Agents Using DNA Damage Markers.

Clin Cancer Res 2019 May 21;25(10):3084-3095. Epub 2019 Feb 21.

Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-2523DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522288PMC
May 2019

Modernizing Clinical Trials for Patients With Cancer.

JAMA 2019 Feb;321(5):447-448

Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2018.18938DOI Listing
February 2019

Guidelines for the Detection of NADPH Oxidases by Immunoblot and RT-qPCR.

Methods Mol Biol 2019 ;1982:191-229

Department of Pathology, Emory University, Atlanta, GA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-9424-3_12DOI Listing
January 2019

Predicting tumor cell line response to drug pairs with deep learning.

BMC Bioinformatics 2018 Dec 21;19(Suppl 18):486. Epub 2018 Dec 21.

Computing, Environment and Life Sciences, Argonne National Laboratory, Lemont, IL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12859-018-2509-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302446PMC
December 2018

Novel clinical indenoisoquinoline topoisomerase I inhibitors: a twist around the camptothecins.

Oncotarget 2018 Dec 18;9(99):37286-37288. Epub 2018 Dec 18.

Yves Pommier: Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://www.oncotarget.com/fulltext/26466
Publisher Site
http://dx.doi.org/10.18632/oncotarget.26466DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324668PMC
December 2018

A Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Carcinomas and Sarcomas.

Oncologist 2018 11 31;23(11):1269-e125. Epub 2018 May 31.

Early Clinical Trials Development Program, Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/lookup/doi/10.1634/th
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2018-0203DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291327PMC
November 2018

What Can Be Done to Improve Research Biopsy Quality in Oncology Clinical Trials?

J Oncol Pract 2018 Oct 4:JOP1800092. Epub 2018 Oct 4.

Frederick National Laboratory for Cancer Research, Frederick; National Cancer Institute, Bethesda MD; Beth Israel Deaconess Medical Center; Harvard Medical School; Massachusetts General Hospital, Boston, MA; American College of Radiology, Reston, VA; and University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JOP.18.00092
Publisher Site
http://dx.doi.org/10.1200/JOP.18.00092DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237512PMC
October 2018

Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors.

J Clin Oncol 2018 06 18;36(16):1594-1602. Epub 2017 Dec 18.

Anish Thomas, Christophe E. Redon, Linda Sciuto, Emerson Padiernos, Min-Jung Lee, Akira Yuno, Sunmin Lee, Arun Rajan, Udayan Guha, Haobin Chen, Raffit Hassan, Christine C. Alewine, Eva Szabo, Seth M. Steinberg, James H. Doroshow, Mirit I. Aladjem, Jane B. Trepel, and Yves Pommier, National Cancer Institute, Bethesda; Jiuping Ji, Yiping Zhang, Lan Tran, William Yutzy, and Robert J. Kinders, Frederick National Laboratory for Cancer Research, Frederick, MD; and Susan E. Bates, Columbia University Medical Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.6915DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978471PMC
June 2018

Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors.

Mol Cancer Ther 2018 03 14;17(3):698-709. Epub 2018 Feb 14.

Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-17-0552DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935559PMC
March 2018

Development of a quantitative pharmacodynamic assay for apoptosis in fixed tumor tissue and its application in distinguishing cytotoxic drug-induced DNA double strand breaks from DNA double strand breaks associated with apoptosis.

Oncotarget 2018 Mar 30;9(24):17104-17116. Epub 2018 Mar 30.

Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.24936DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908309PMC
March 2018

On the Design of Combination Cancer Therapy.

Cell 2017 12;171(7):1476-1478

Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2017.11.035DOI Listing
December 2017

Longitudinal Transcriptional Response of Glycosylation-Related Genes, Regulators, and Targets in Cancer Cell Lines Treated With 11 Antitumor Agents.

Cancer Inform 2017 15;16:1176935117747259. Epub 2017 Dec 15.

Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, USA.

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1176935117747259
Publisher Site
http://dx.doi.org/10.1177/1176935117747259DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5734428PMC
December 2017

Characterization of potent and selective iodonium-class inhibitors of NADPH oxidases.

Biochem Pharmacol 2017 11 11;143:25-38. Epub 2017 Jul 11.

Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcp.2017.07.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610936PMC
November 2017

Decoding NADPH oxidase 4 expression in human tumors.

Redox Biol 2017 10 26;13:182-195. Epub 2017 May 26.

Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA; Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, MD 20892, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.redox.2017.05.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458090PMC
October 2017

First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.

J Clin Oncol 2017 Oct 30;35(30):3391-3400. Epub 2017 Aug 30.

Matthew P. Goetz, Vera J. Suman, Joel M. Reid, Don W. Northfelt, Michael A. Mahr, Andrew T. Ralya, Mary Kuffel, Sarah A. Buhrow, Stephanie L. Safgren, Renee M. McGovern, John Black, Travis Dockter, Tufia Haddad, Charles Erlichman, Alex A. Adjei, Dan Visscher, Benjamin R. Kipp, Minetta C. Liu, John R. Hawse, Matthew M. Ames, and James N. Ingle, Mayo Clinic, Rochester, MN; Zachary R. Chalmers and Garrett Frampton, Foundation Medicine, Cambridge, MA; and John R. Hawse, James H. Doroshow, Jerry M. Collins, and Howard Streicher, National Cancer Institute, Bethesda, MD.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.73.3246
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.73.3246DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648176PMC
October 2017

Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis).

J Clin Oncol 2017 May 28;35(14):1561-1569. Epub 2017 Mar 28.

Shivaani Kummar, Geraldine O'Sullivan Coyne, Khanh T. Do, Baris Turkbey, Paul S. Meltzer, Eric Polley, Peter L. Choyke, Robert Meehan, Yvonne Horneffer, Ann Lih, Amul Choudhary, Sandra A. Mitchell, Lee J. Helman, James H. Doroshow, and Alice P. Chen, National Cancer Institute, National Institutes of Health, Bethesda; and Rasa Vilimas and Lamin Juwara, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.1994DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455706PMC
May 2017

Deficiency in Duox2 activity alleviates ileitis in GPx1- and GPx2-knockout mice without affecting apoptosis incidence in the crypt epithelium.

Redox Biol 2017 04 22;11:144-156. Epub 2016 Nov 22.

Department of Cancer Genetics and Epigenetics, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.redox.2016.11.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5148781PMC
April 2017

PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.

Drugs 2017 Feb;77(2):113-130

Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Room 3A44, Bethesda, MD, 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-016-0688-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266774PMC
February 2017

Effective implementation of novel MET pharmacodynamic assays in translational studies.

Ann Transl Med 2017 Jan;5(1)

Laboratory of Human Toxicology and Pharmacology, Applied/Developmental Research Directorate, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm.2016.12.78DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5253289PMC
January 2017

Concerted changes in transcriptional regulation of genes involved in DNA methylation, demethylation, and folate-mediated one-carbon metabolism pathways in the NCI-60 cancer cell line panel in response to cancer drug treatment.

Clin Epigenetics 2016 24;8:73. Epub 2016 Jun 24.

Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, 9609 Medical Center Dr., Rockville, MD 20850 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13148-016-0240-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919895PMC
December 2016

NADPH oxidase-1 deficiency offers little protection in -induced typhlitis in mice.

World J Gastroenterol 2016 Dec;22(46):10158-10165

Fong-Fong Chu, Department of Gastroenterology and Hepatology, The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, Henan Province, China.

View Article

Download full-text PDF

Source
http://www.wjgnet.com/1007-9327/full/v22/i46/10158.htm
Publisher Site
http://dx.doi.org/10.3748/wjg.v22.i46.10158DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5155175PMC
December 2016

Theory and practice of clinical pharmacodynamics in oncology drug development.

Semin Oncol 2016 08 26;43(4):427-35. Epub 2016 Jul 26.

Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2016.07.001DOI Listing
August 2016

Establishing proof of mechanism: Assessing target modulation in early-phase clinical trials.

Semin Oncol 2016 08 14;43(4):446-52. Epub 2016 Jun 14.

National Cancer Institute, National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2016.06.002DOI Listing
August 2016

Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations.

Semin Oncol 2016 08 16;43(4):501-13. Epub 2016 Jun 16.

Vaccine Branch, National Cancer Institute, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2016.06.008DOI Listing
August 2016

Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development.

Semin Oncol 2016 08 26;43(4):514-25. Epub 2016 Jul 26.

Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2016.07.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5117459PMC
August 2016

Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays.

Clin Cancer Res 2016 07 21;22(14):3683-94. Epub 2016 Mar 21.

Laboratory of Human Toxicology and Pharmacology, Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-2323DOI Listing
July 2016

Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations.

J Exp Clin Cancer Res 2016 Mar 31;35:56. Epub 2016 Mar 31.

National Institutes of Health, National Cancer Institute, Center for Cancer Research, Laboratory of Molecular Pharmacology, 37 Convent Drive, Building 37, Room 5068, Bethesda, MD, 20892-4255, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13046-016-0335-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815242PMC
March 2016

Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial.

J Mol Diagn 2016 Jan 18;18(1):51-67. Epub 2015 Nov 18.

Molecular Characterization and Clinical Assay Development Laboratory, Leidos Biomedical Research Inc., and Frederick National Laboratory for Cancer Research, Frederick, Maryland; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmoldx.2015.07.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5812775PMC
January 2016

NCI-60 whole exome sequencing and pharmacological CellMiner analyses.

PLoS One 2014 17;9(7):e101670. Epub 2014 Jul 17.

Developmental Therapeutic Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America; Developmental Therapeutic Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0101670PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102467PMC
December 2015

Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors.

J Clin Oncol 2015 Oct 11;33(30):3409-15. Epub 2015 May 11.

Khanh Do, Jennifer Zlott, Jerry Collins, Alice P. Chen, James H. Doroshow, and Shivaani Kummar, National Cancer Institute, Bethesda, MD; Deborah Wilsker, Jiuping Ji, and Robert J. Kinders, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD; and Tomoko Freshwater, Merck Research Laboratories-Oncology, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.4009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4606059PMC
October 2015

Oral and intravenous pharmacokinetics of 5-fluoro-2'-deoxycytidine and THU in cynomolgus monkeys and humans.

Cancer Chemother Pharmacol 2015 Oct 1;76(4):803-11. Epub 2015 Sep 1.

Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA, 15213, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-015-2857-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4573928PMC
October 2015

Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60.

Clin Cancer Res 2015 Sep 5;21(17):3841-52. Epub 2015 Jun 5.

Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-0335DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558215PMC
September 2015

Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer.

Invest New Drugs 2015 Jun 1;33(3):720-8. Epub 2015 Feb 1.

Division of Cancer Treatment and Diagnosis, National Cancer Institute, 31 Center Drive, Bldg 31, Rm 3A44, Bethesda, MD, 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-015-0212-zDOI Listing
June 2015

NADPH oxidases and cancer.

Clin Sci (Lond) 2015 Jun;128(12):863-75

*Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1042/CS20140542DOI Listing
June 2015

Application of molecular profiling in clinical trials for advanced metastatic cancers.

J Natl Cancer Inst 2015 Apr 6;107(4). Epub 2015 Feb 6.

Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (SK, ECP, APC, LVR, YZ, RMS, BAC, JHD); Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD (PMW, CJL).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djv003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334817PMC
April 2015

Alterations of DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity.

DNA Repair (Amst) 2015 Apr 11;28:107-15. Epub 2015 Feb 11.

Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15687864150002
Publisher Site
http://dx.doi.org/10.1016/j.dnarep.2015.01.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4385398PMC
April 2015

Notch1 phenotype and clinical stage progression in non-small cell lung cancer.

J Hematol Oncol 2015 Feb 6;8. Epub 2015 Feb 6.

National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-014-0104-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4343190PMC
February 2015

National Cancer Institute-supported clinical trials networks.

J Clin Oncol 2015 Jan 1;33(3):293. Epub 2014 Dec 1.

National Cancer Institute, National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.5421DOI Listing
January 2015

Translational research in oncology--10 years of progress and future prospects.

Nat Rev Clin Oncol 2014 Nov 7;11(11):649-62. Epub 2014 Oct 7.

Division of Cancer Treatment and Diagnosis, Room 3A-44, Building 31, 31 Center Drive, National Cancer Institute, NIH, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2014.158DOI Listing
November 2014

Identification of novel PARP inhibitors using a cell-based TDP1 inhibitory assay in a quantitative high-throughput screening platform.

DNA Repair (Amst) 2014 Sep 29;21:177-82. Epub 2014 Apr 29.

Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.dnarep.2014.03.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4125495PMC
September 2014

Validation of a hypoxia-inducible factor-1 alpha specimen collection procedure and quantitative enzyme-linked immunosorbent assay in solid tumor tissues.

Anal Biochem 2014 Aug 4;459:1-11. Epub 2014 May 4.

Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA; Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00032697140017
Publisher Site
http://dx.doi.org/10.1016/j.ab.2014.04.025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810780PMC
August 2014

NADPH oxidases: a perspective on reactive oxygen species production in tumor biology.

Antioxid Redox Signal 2014 Jun 24;20(17):2873-89. Epub 2013 Oct 24.

1 Laboratory of Molecular Pharmacology of the Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/ars.2013.5603DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4026372PMC
June 2014

Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.

J Pharmacol Exp Ther 2014 Jun 20;349(3):408-16. Epub 2014 Mar 20.

Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research (Ju.M., J.H.D., Y.P.), National Clinical Target Validation Laboratory (Y.Z., J.J.), and Division of Cancer Treatment and Diagnosis (Jo.M., J.H.D.), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; and Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan (Ju.M., S.T.).

View Article

Download full-text PDF

Source
http://jpet.aspetjournals.org/cgi/doi/10.1124/jpet.113.21014
Publisher Site
http://dx.doi.org/10.1124/jpet.113.210146DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4019318PMC
June 2014

Molecular analysis for therapy choice: NCI MATCH.

Semin Oncol 2014 Jun 22;41(3):297-9. Epub 2014 May 22.

Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2014.05.002DOI Listing
June 2014

Molecular mechanisms underlying chronic inflammation-associated cancers.

Cancer Lett 2014 Apr 26;345(2):164-73. Epub 2013 Aug 26.

Laboratory of Molecular Pharmacology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2013.08.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3935998PMC
April 2014

Nox1 causes ileocolitis in mice deficient in glutathione peroxidase-1 and -2.

Free Radic Biol Med 2014 Mar 25;68:315-25. Epub 2013 Dec 25.

Department of Radiation Biology and Beckman Research Institute, City of Hope, Duarte, CA 91010, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.freeradbiomed.2013.12.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943970PMC
March 2014

Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.

Mol Cancer Ther 2014 Feb 19;13(2):433-43. Epub 2013 Dec 19.

Corresponding Author: Yves Pommier, Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, 37 Convent Drive, Building 37, Room 5068, NIH, Bethesda, MD 20892-4255.

View Article

Download full-text PDF

Source
http://mct.aacrjournals.org/cgi/doi/10.1158/1535-7163.MCT-13
Publisher Site
http://dx.doi.org/10.1158/1535-7163.MCT-13-0803DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946062PMC
February 2014

The Gdac1 locus modifies spontaneous and Salmonella-induced colitis in mice deficient in either Gpx2 or Gpx1 gene.

Free Radic Biol Med 2013 Dec 1;65:1273-1283. Epub 2013 Oct 1.

Department of Radiation Biology, Beckman Research Institute, City of Hope, Duarte, CA 91010, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S08915849130061
Publisher Site
http://dx.doi.org/10.1016/j.freeradbiomed.2013.09.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875339PMC
December 2013

Overcoming resistance to targeted anticancer drugs.

Authors:
James H Doroshow

N Engl J Med 2013 Nov 1;369(19):1852-3. Epub 2013 Nov 1.

From the Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMe1311325DOI Listing
November 2013

An audit strategy for time-to-event outcomes measured with error: application to five randomized controlled trials in oncology.

Clin Trials 2013 Oct 9;10(5):754-60. Epub 2013 Aug 9.

aBiostatistics Research Branch, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1740774513493973DOI Listing
October 2013

Wee1 kinase as a target for cancer therapy.

Cell Cycle 2013 Oct 26;12(19):3159-64. Epub 2013 Aug 26.

Center for Cancer Research; National Cancer Institute; Bethesda, MD USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cc.26062DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3865011PMC
October 2013

Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration.

BMC Med 2013 Oct 17;11:220. Epub 2013 Oct 17.

Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Room 5W130, MSC 9735, 9609 Medical Center Drive, Bethesda, MD 20892-9735, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1741-7015-11-220DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3852338PMC
October 2013

Timely completion of scientifically rigorous cancer clinical trials: an unfulfilled priority.

Authors:
James H Doroshow

J Clin Oncol 2013 Sep 19;31(27):3312-4. Epub 2013 Aug 19.

National Cancer Institute, National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.51.3192DOI Listing
September 2013

The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.

Cancer Res 2013 Jul 15;73(14):4372-82. Epub 2013 Jul 15.

Genetics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research, and Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, MD 20982, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-12-3342DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4893961PMC
July 2013